Home
>
US Stocks
>
Pliant Therapeutics Inc
Pliant Therapeutics Inc
PLRX

Pliant Therapeutics Inc (PLRX)

$16.836.6%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
$16.86
Today Low/High
$16.7 / $17.33
52 Week Low/High
$18.28 / $43.92
Market Cap
$684.62M

Company Details

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Organisation
Pliant Therapeutics Inc
Headquaters
South San Francisco, California, US
Employees
78
Industry
Health Technology
CEO
Bernard Coulie

Discover more

Frequently Asked Questions

What is Pliant Therapeutics Inc (PLRX) share price today?

Can Indians buy Pliant Therapeutics Inc (PLRX) shares?

How can I buy Pliant Therapeutics Inc (PLRX) shares from India?

Can Fractional shares of Pliant Therapeutics Inc (PLRX) be purchased?

What are the documents required to start investing in Pliant Therapeutics Inc (PLRX) stocks?

We are a SEBI registered investement advisor